Gaithersburg, MD – According to filings with the U.S. Securities and Exchange Commission, Adaptive Phage Therapeutics is raising $7,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Greg Merril played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Adaptive Phage Therapeutics

Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. Two key components of APT’s approach are 1) PhageBank, a large and dynamically growing collection of bacteriophages or phages (viruses that attack specific targeted bacteria) and 2) an innovative rapid system for matching phage to patient-specific bacterial infections. In 2016 APT’s approach achieved its first in-human success with the rescue of a critically ill MDR infected patent.

To learn more about Adaptive Phage Therapeutics, visit http://www.aphage.com/

Contact:
Greg Merril, Chief Executive Officer
240-899-2532
gmerril@aphage.com
https://www.linkedin.com/in/greg-merril-11aab31/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved